BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 11684562)

  • 1. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
    Lee WC; Wu MJ; Cheng CH; Chen CH; Shu KH; Lian JD
    Am J Kidney Dis; 2001 Nov; 38(5):1074-81. PubMed ID: 11684562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
    Murakami R; Amada N; Sato T; Orii T; Kikuchi H; Haga I; Ohashi Y; Okazaki H
    Clin Transplant; 2006; 20(3):351-8. PubMed ID: 16824154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
    Yen TH; Huang CC; Lin HH; Huang JY; Tian YC; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH
    Nephrol Dial Transplant; 2006 Apr; 21(4):1046-52. PubMed ID: 16390851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
    Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
    J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
    Joh JW; Lee HH; Park JW; Lee DH; Yoo BC; Lee KW; Kim SJ
    Transplant Proc; 2005 Mar; 37(2):1235-7. PubMed ID: 15848680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
    Ben-Ari Z; Broida E; Kittai Y; Chagnac A; Tur-Kaspa R
    Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
    Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
    Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
    Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.